Despite the potential relevance of the L-arginine-nitric oxide (NO) pathway in the pathophysiology of pulmonary hypertension, no in vivo studies of the kinetics of arginine and NO have been conducted previously in this population. The terminal guanidino N-atom of L-arginine is the precursor for NO, which is oxidized to the stable inorganic nitrogen oxides, nitrite (NO,-) and nitrate (NO,-). Thus, synthesized NO is detected in serum or urine as NO,-and NO,-. The purpose of this investigation was to compare studies of whole body arginine metabolism twice in nine patients with persistent pulmonary hypertension of the newborn (PPHN), using a primed constant i.v. infusion of ~-[~uanidino-~~N,,5,5~H,]ar~inine and L- [5,5,52~,]leucine, first during acute pulmonary vasoconstriction and again during convalescence, and thereby to characterize quantitative aspects of whole body arginine kinetics and NO production, as estimated from the rate of transfer of the '5~-guanidino-label of arginine to urinary nitrate (ISNO,-). Arginine flux rates were 84.1 ? 8.6 p r n~l -k~. -~h -~ (mean ? SEM) during acute pulmonary hypertension and increased to 125 ? 13.2 ( p < 0.05) during conva-PPHN is an acute vascular maladaptation to extrauterine life, characterized by reactive pulmonary vasoconstriction, causing extrapulmonary shunting of blood across fetal channels and critical hypoxemia. Remodeling of the pulmonary arteries has been observed in some patients with PPHN (1). The etiology of this disorder is uncertain, but a role for altered NO production, a recently discovered key regulator of vascular tone (2-4), Received October 10, 1994; accepted February 27, 1995 Abbreviations PPHN, persistent pulmonary hypertension of the newborn NO, nitric oxide eNOS, nitric oxide synthase AaDO,, alveolo-arterial oxygen gradient ECMO, extracorporeal membrane oxygenation A.P.E., atom percent excess must be considered. NO is produced in the pulmonary and systemic arteries of newborn animals (5) and contributes to the postnatal vasodilation of the pulmonary circulation (6, 7). NO is synthesized in the endothelial cells, through the action of eNOS, and diffuses into subjacent vascular smooth muscle, where it binds to its molecular target, the prosthetic heme group of soluble guanylyl cyclase, forming nitrosyl proteins (8). This process activates guanylyl cyclase, augmenting levels of the second messenger, cGMP (8). Intracellular elevation of cGMP levels activates cGMP-dependent protein kinases, leading to phosphorylation of proteins and inhibition of intracellu-MA 02114. lar calcium release and/or influx through calcium channels.
PPHN is an acute vascular maladaptation to extrauterine life, characterized by reactive pulmonary vasoconstriction, causing extrapulmonary shunting of blood across fetal channels and critical hypoxemia. Remodeling of the pulmonary arteries has been observed in some patients with PPHN (1) . The etiology of this disorder is uncertain, but a role for altered NO production, a recently discovered key regulator of vascular tone (2-4),
The terminal guanidino N-atom of t-arginine is the precursor of NO, which is synthesized in cells by a cytokine-induced, high output L-arginine-NO pathway as well as a constitutive low output pathway (3) . NO formed by either pathway undergoes oxidative degradation to the stable inorganic nitrogen oxides, nitrite (NO2-) and nitrate (NO3-). In the in vivo system NO2-is oxidized to NO3-via hemoglobin, thus NO can be eventually detected in serum or urine as NO3- (9, 10) .
Despite the biochemical importance of arginine as the precursor for NO, little is known about the in vivo regulation of arginine metabolism or how it varies during human pathophysiology. It has been shown that in some pathologic states, such as hypercholesterolemia (ll), intimal hyperplasia post-balloon catheterization injury (12) , or hypoxia (13, 14) , endothelial dysfunction may be reversed or attenuated by administration of L-arginine, the precursor of NO.
Arginine, via ornithine, is also the precursor for polyamines (spermine, spermidine, and putrescine). These low molecular weight cations play an important role in the pulmonary arteries' remodeling during chronic hypoxemia (15) (16) (17) . It appears, then, that these two important metabolites of arginine (NO and polyamines) are related to the main pathophysiologic events of PPHN: vasoconstriction and remodeling of the pulmonary arteries.
In this study, we examined whole body arginine and protein metabolism and NO production twice in infants with PPHN, first during acute pulmonary vasoconstriction and again during convalescence. We used a primed constant i.v. infusion of ~-['~~]~uanidino-labeled arginine and leucine cine to characterize quantitative aspects of arginine and protein kinetics in these patients. NO production was estimated by the rate of transfer of the ["~]~uanidino label of arginine to urinary 1 5~0 , -. Due to arginine7s precursor role for NO, we hypothesized that the L-arginine-NO metabolic pathway is altered during PPHN, resulting in a decreased rate of NO synthesis and therefore pulmonary vasoconstriction. We wished to address the following questions. I ) Is whole body arginine and protein metabolism different during the acute phase of PPHN when compared to convalescence? 2) Is the utilization of plasma arginine for whole body NO synthesis altered during PPHN?
METHODS

Patients.
Nine sequential critically ill newborns with a diagnosis of PPHN confirmed by echocardiogram were investigated. The echocardiogram showed right to left shunting in all patients. Two patients (nos. 3 and 8) were shunting only through the ductus arteriosus, and the remaining seven patients were shunting through the foramen ovale and the ductus arteriosus. Pulmonary artery pressure was estimated by measurement of the doppler tricuspid regurgitation velocity jet and an assumed right atrial pressure of 10, in patients without continuous right atrial pressure measurement. Seven patients had suprasystemic and two patients had systemic pulmonary artery pressure. The mean + SEM systolic pulmonary pressure was 46 + 1.8 with a range of 37 to 54 Torr. Seven patients also had a diagnosis of meconium aspiration, one patient had blood aspiration, and one patient had primary PPHN. Patients with liver or renal failure, those treated with any nitrite-nitrate containing medication, or those with evidence of infection were excluded. The clinical characteristics of the patients are described in Table 1 . All patients were outborn and transferred to the Neonatal Intensive Care Unit at the Massachusetts General Hospital. The patients were first studied within 24 h after admission, during acute hypoxemia with an AaDO, of 81 + 1.9 kPa (609 t-7 Torr, mean + SEM), at 3.1 + 0.3 d of age, and again during convalescence, AaDO, 19.5 f 0.9 kPa (146 + 4 Torr), at 6.9 + 0.7 d of age. We used the Neonatal Physiologic Stability Index (18) and the Therapeutic Intervention Score System (19) to assess the severity of disease and the respectively, for arginine and leucine. Leucine was used to provide a comparative index of the overall status of amino acid metabolism (21) . Verification of isotopic purity was obtained before the infusion study. Labeled tracers were confirmed to be sterile and pyrogen-free before use. Both tracer solutions were infused at a rate of 2.5 m1.h-' in all patients. We used the arterial line as the sampling source and a central venous line for tracer infusion. In the ECMO patients the isotopes were infused via the venous cannula placed in the internal jugular vein, at the pre-membrane site for the first study. During the second study, a central or peripheral venous line was used for tracer infusion, and blood was sampled from an arterial line. Isotope tracers were infused by means of a calibrated syringe pump (Harvard Apparatus, Natick, MA).
Blood samples were obtained at 0, 120, 180,210, and 240 min, to measure plasma isotopic enrichment of both amino acid tracers. Blood samples were placed in tubes containing heparin and centrifuged immediately, and plasma was stored at -80°C until analysis. Twenty four-hour urine collection beginning with the tracer infusion study was obtained under sterile conditions via a Foley catheter, and sterility was confirmed by a negative urine culture.
Nutritional support. All patients received variable levels of protein and energy intake with a nitrate-free total parenteral nutrition ( Table 2 ). The composition of the amino acid mixture used (Novamine 11.4%, Clinitec, Deerfield, IL), has been previously reported (22) . The duration of nutritional support previous to the acute tracer infusion was variable (0.6 + 0.3 d), with patient nos. 1, 5, 6, 7, and 9 remaining on nothing by mouth during the first infusion study. All patients were receiving parenteral nutrition for 4 + 0.4 d during the second tracer infusion study.
Analytical methods. We used 300 p1 of plasma to determine the isotopic enrichment of [15~2]arginine and [2~,]leucine by gas chromatography-mass spectrometry as previously described (23) , all enrichments were determined against calibration standards, and values are expressed as mole fractions above the value for blood drawn before tracer administration.
A complete 24-h urine collection was obtained for 1 5~ enrichment and total nitrate determinations. Urine was collected in dark polyethylene bottles containing sodium hydroxide and stored at -20°C until analyzed. The 15N enrichment of urinary nitrate was measured by converting nitrate to nitrobenzene, as previously described (24) . Urinary nitrate was measured utilizing an automated procedure (24) .
Calculations. We used the standard steady state isotope dilution equation to determine plasma arginine (Q,,,) and leucine (Q,,,) flux as follows (25): where i is the rate of the tracer infusion (prn01.k~-'h-') and Ei and Ep are the isotopic enrichments of the infusate and plasma amino acid, respectively. The constant -1 corrects for the tracer infused. Plasma leucine enrichment, not ketoisocaproic acid, was used to estimate the leucine flux. The rate of urinary 15N0,-excretion (prno1.d-l) was derived by the following equation:
where total urinary NO,-is the amount of nitrate excreted in urine and enrichment of urinary 15N is expressed as A.P.E. (23) .
The percentage of the [15N,]arginine tracer infused that was used for labeling NO was calculated as follows: The rate of conversion of plasma arginine to NO ( Q, , , , , ; pmo1.d-l) was derived as follows: The rates of whole body protein turnover (synthesis and breakdown) were obtained assuming the leucine content of whole body mixed protein to be 361.3 pmol/gram of protein and from nitrogen balance (g ~. k g -~' d -l X 6.25) (26).
Data analysis.
Results are presented as mean + SEM.
Primary and derived values were tested for significance between acute illness and convalescence using a paired t test with p < 0.05 taken as significant. The relationship between arginine intake and the percentage of 15N2 tracer infused, used for NO formation, was evaluated by least squares linear regression analysis. An SAS program (27) was employed for statistical analysis.
RESULTS
During the 4-h continuous tracer infusion period a steady state level of isotopic enrichment of both the plasma leucine and arginine pools was achieved in our patients (Fig. 1 ). There was a tendency for plasma arginine and for leucine enrichment to increase toward the end of the 4-h period when patients were studied during acute pulmonary vasoconstriction. For all nine patients the mean coefficients of variation for plateau plasma isotope enrichment, based on samples drawn during the last 2 h, were 13.3 and 13.9% for ~-[~u a n i d i n o -~~N , , 5 , 52~2]arginine, and 3.7 and 5.8% for L-[2~,]leucine during PPHN and convalescence, respectively. From these isotopic enrichments, plasma arginine and leucine kinetics were calculated (Tables 3 and 4) . Arginine enrichments were lower ( p < 0.05) during convalescence than in the acute phase of illness. (Fig. 2) , but there was no correlation during acute PPHN.
DISCUSSION
We have investigated whole body arginine metabolism and NO production in critically ill newborns with PPHN. Despite the potential relevance of the L-arginine-NO pathway in the pathophysiology of pulmonary hypertension, no in vivo studies of the kinetics of arginine and NO have been conducted previously in this population. Due to ethical considerations, a healthy cohort was not investigated, therefore, each patient served as histher own control during convalescence. The use of 22 CASTILLO ET AL. ECMO in patient nos. 1, 2, 4, and 6 raised concerns regarding its effect on tracer kinetics. However, there was not difference in arginine kinetics, urinary enrichment, nitrate, and 15N0,-between the patients treated with ECMO and those who re- This study reveals marked differences in whole body NO production and in the pattern of utilization of plasma arginine between the acute and convalescent phases in infants with PPHN. During the acute phase of the disease, the total urinary output of NO,-was about 60% of that during convalescence, suggesting a reduced conversion of the guanidino-N of arginine to NO and citrulline, via the action of NO synthase. The reduced urinary excretion of 15N0,-after the i.v. infusion of 15~-labeled arginine confirmed a diminished activity of the L-arginine-NO pathway, for 15N0,-originates only from the [lS~]guanidino label of the arginine infused. Urinary nitrate excretion is dependent on adequate renal function, nitrate intake, and the presence of nitrate-producing bacteria (29, 30) . The normal creatinine clearance values obtained in these patients, during acute pulmonary hypertension and convalescence, excluded the possibility of altered renal function during the acute, critically ill period and therefore decreased urinary excretion, rather than production of 15N0,-. In addition, the patients received nitrate-free parenteral nutrition and only patients without infection were included in the study. Thus, the possibility of "contamination" during convalescence with exogenous sources of nitrate was ruled out. With clinical improvement our patients received a higher intake of arginine, and the total arginine flux was higher in convalescent patients compared with that of acute illness. The leucine fluxes, however, were unchanged by the leucine intake and remained within the range of values reported in healthy newborns (21, 28 ). It would appear, then, that diet may have influenced arginine, but not leucine, metabolism. Furthermore, there was a significant correlation between dietary arginine intake during convalescence and the percentage of [15N,]arginine tracer utilized for NO synthesis (Fig. 2) . It is conceivable, therefore, that the higher intake and higher plasma arginine flux may promote the formation of NO, and that this also resulted in plasma arginine being the preferred substrate source for the eNOS reaction. An intervention study might help to determine whether this is so and also whether exogenous arginine would help to attenuate pulmonary hypertension. It should also be noted that the mean difference in arginine intakes between the acute and convalescent phases was about 16 pmol kg.-'hK1, equivalent to 69 mg arginine kg.-'dC1 or a protein intake of about 1 g.kg.-'d-l, which in both cases are nutritionally significant levels. Indeed protein balance was improved during convalescence. Also, a developmental matu-ration in arginine metabolism between d 3.1 versus d 6.9 of life would be difficult to sustain, because this process would selectively affect arginine and not leucine, which is an essential and nutritionally more "important" amino acid.
From our tracer data we are led to the conclusion that plasma arginine is used to a relatively lesser extent for NO synthesis during acute PPHN compared with that during convalescence. Whether the reduced in vivo activity of the eNOS reaction, which these data suggest, is due primarily to a change in the level and regulation of eNOS (8, 31, 32) and/or to changes in the metabolism and tissue availability of arginine (13, (33) (34) (35) cannot be determined from this study. The differences in the relative utilization of plasma arginine for NO synthesis between acute and convalescent PPHN, coupled with the intake differences mentioned above, make it relevant to recall that there is extensive compartmentation of arginine metabolism in vivo, at the intracellular, intraorgan, and interorgan levels (36) (37) (38) (39) (40) , and although plasma arginine is made available during a complete turn of the urea cycle (Fig. 3) , vascular endothelial cells, when stimulated, can exhibit a "direct" metabolic pathway whereby the citrulline produced by the action of the eNOS is directly converted to arginine thanks to the action of the argininosuccinate synthase and argininosuccinate lyase. Therefore, this L-arginine-NO-citrulline+~-arginine cycle enables intracellular arginine availability and NO production (41) . An impairment in NO and citrulline production may also limit intracellular arginine availability, and this may lead to a greater dependence on plasma arginine and/or exogenous sources. It has been demonstrated in animal and human studies that, under some pathologic conditions, such as induced pulmonary hypertension (34), hypoxia (13, 14) , and hypercholesterolemia (11, 42) , the administration of L-arginine may reverse or attenuate vasoconstriction. These studies suggest the concept that arginine availability may become a rate-limiting step in NO formation. The factors that affect arginine utilization and availability have not been clearly established. Due to the tight compartmentation of arginine metabolism, it is likely that different factors influence arginine availability at different levels. It is known that altered extracellular concentrations of L-lysine and L-ornithine competitively inhibit arginine transport; hence, extracellular concentrations of these amino acids can regulate cellular NO synthesis (43) . The effect of hypoxemia or acid-base changes in plasma or intracellular arginine utilization remains to be established.
It also has been shown that rat liver arginase is inhibited by @-hydroxy-L-arginine, an intermediate in the biosynthesis of NO from L-arginine (44) , favoring the utilization of arginine as a substrate for eNOS. If this inhibition would occur also in lung arginase, a decreased formation of NO and citrulline would not only limit arginine availability, but also would limit inhibition of arginase, therefore channeling arginine toward urea and ornithine. There is evidence in recent investigations that in some pathophysiologic states, such as glomerulonephritis (45) and wound healing (46) , there is a temporal expression of these two different pathways of L-arginine metabolism (Larginine+ornithine pathway and the L -a r g i n i n e j N 0 -citrulline pathway), depending on the pathophysiologic state. We speculate that, although it is possible that the etiology of pulmonary vasoconstriction and remodeling of the pulmonary arteries is perhaps multifactorial, involving growth factors (47), endothelins (48) , and nitric oxide (4), a preferential direction of arginine metabolism toward the formation of ornithine and polyamines resulting in smooth muscle proliferation and remodeling of the pulmonary arteries, with a concomitant fall in the activity of the L-arginine-NO-citrulline pathway leading to pulmonary vasoconstriction and hypertension, may contribute to this pathology (Fig. 4) . In view of the limitations in the interpretation of whole body metabolic tracer studies, further investigations aimed to assess the in vivo quantitative significance and relationships among these pathways of arginine metabolism during pulmonary hypertension at the pulmonary level are necessary. Estimation of the stoichiometric L-arginine-+NO-citrulline pathway by measurement of labeled [15~]citrulline and investigations of the ornithinepolyamine pathway by measurement of 'H,-labeled polyamines should further improve our understanding of the complex interactions between arginine metabolism, NO synthesis, and the pathophysiologic events that take place in PPHN. Although additional, comparable data in normal healthy infants would be strongly desirable, ethical considerations regarding the use of invasive studies in healthy newborns excluded this possibility.
In summary, we describe here, apparently for the first time, whole body arginine metabolism and NO production in pa- tients with PPHN. From these observations we conclude that plasma arginine utilization for whole body NO synthesis is decreased during the acute vasoconstrictive state of PPHN and suggest the concept that arginine availability may become an important factor in NO formation. We are fully aware that the present study is limited by the variable clinical conditions and nutritional support of our patients, the reduced sample size, and the absence of healthy controls. Although these difficulties are often present in clinical investigations involving critically ill patients, we believe that, given the biological relevance of the L-arginine-NO pathway, it is important to begin to explore in vivo quantitative aspects of arginine metabolism in these patients. We propose that further studies at the pulmonary level will yield organ-specific information regarding the metabolism of arginine during PPHN.
